AKRO Profile
Akero Therapeutics Inc. (AKRO) is a clinical-stage biotechnology company that focuses on developing and commercializing treatments for serious metabolic diseases with unmet medical needs. The company's lead product candidate, Efruxifermin (formerly AKR-001), is an engineered human FGF21 molecule that is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and other metabolic diseases.
Akero's platform technology is based on a discovery made at the University of California, San Francisco, where researchers found that the FGF21 protein has the potential to treat a range of metabolic diseases, including NASH, type 2 diabetes, and obesity. The company's technology enables the development of engineered FGF21 molecules that have improved properties, such as longer half-lives and increased potency.
The company completed its initial public offering (IPO) in June 2019 and is headquartered in South San Francisco, California.
As of September 2021, Akero has a market capitalization of approximately $1.2 billion. The company's shares are traded on the Nasdaq Global Select Market under the ticker symbol "AKRO."
|
